Insiders · HRTX

Thomas Cusack

Director at Heron Therapeutics, Inc. /de/ (HRTX) since October 2025

Thomas Cusack has filed 3 insider reports with the SEC since November 2025, as director at Heron Therapeutics, Inc. /de/ (HRTX). The latest filing, on February 3, 2026, reports grant or award at Heron Therapeutics, Inc. /de/ (HRTX).

Filings
3
Companies
1
Bought on market
None
Sold on market
None

Companies where Thomas Cusack is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Heron Therapeutics, Inc. /de/ logo
HRTX
Heron Therapeutics, Inc. /de/
Directorsince October 202553,960$0.2525Feb 3, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Thomas Cusack with

Other insiders at the same companies

Questions about Thomas Cusack

What is Thomas Cusack's role at Heron Therapeutics, Inc. /de/?
Thomas Cusack reports to the SEC as director at Heron Therapeutics, Inc. /de/ (HRTX), according to the latest filing on February 3, 2026.
How many shares does Thomas Cusack own?
After the latest filing that states it, Thomas Cusack directly owned 53,960 shares of Heron Therapeutics, Inc. /de/ (HRTX). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Thomas Cusack bought or sold stock recently?
No open-market purchases or sales by Thomas Cusack are on file. The filings report grant or award.
How do I get alerts when Thomas Cusack files?
Follow Thomas Cusack on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Thomas Cusack (SEC CIK 0002094824). Totals count each trade once, skipping amendments whose original is on file, from Nov 7, 2025 on. View on SEC EDGAR · Get this as JSON